Evidence map›Paper›PMID 18322716›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2008

Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.

C A Martin, A D Hoven, A M Cook

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01367821 (Quorum Sensing Signal Molecules), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01367821 unknown statusnot on this mapstarted 2011, after this paper: background citation

Quorum Sensing Signal Molecules (QSSMs) and Immune Dysfunction in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) for Obstructive Jaundice

TypeobservationalSponsorUniversity of NottinghamRan2011 to 2012Enrolled50ConditionsObstructive Jaundice, Disease as Reason for ERCP, Immune Dysfunction, Immune Tolerance
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 49 citations in OpenAlex.

  1. Screening of Bacterial Quorum Sensing Inhibitors in aPharmaceuticals (Basel, Switzerland) · 2020
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Quorum sensing and phytochemicals.International journal of molecular sciences · 2013
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. The post-antibiotic era: promising developments in the therapy of infectious diseases.International journal of biomedical science : IJBS · 2010
    Article
  16. The quorum-quenching N-acyl homoserine lactone acylase PvdQ is an Ntn-hydrolase with an unusual substrate-binding pocket.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

C A MartinUK HealthCare, University of Kentucky College of Pharmacy, 800 Rose St. H110, Lexington, KY, 40536-0293. USA. cmart2@email.uky.edu
A D Hoven
A M Cook
University of Kentucky · USUniversity of Kentucky HealthCare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Density-dependent cell-cell communication, or quorum sensing (QS), has been demonstrated in numerous species of bacteria. The basic function of QS is likely to confer a nutritional advantage, particularly in a highly populated, mixed-species environment. QS also has ramifications on the production of colonization and virulence factors. Pheromone-like substances secreted into the extracellular milieu appear to govern many of the transcription products in these bacteria. At a high cell density, the QS systems are triggered, and the transcription of the colonization factors are suppressed and replaced by the expression of virulence factors. Major pathogens, such as Pseudomonas aeruginosa and Staphylococcus aureus, have evolved with numerous QS circuits, which modulate the production of various toxins and regulate parallel QS systems. Several QS-modulating therapies, such as macrolide antibiotics, QS vaccines, and competitive QS inhibitors, have been investigated and may prove to be helpful in diminishing the translation of QS-directed toxins or by prematurely activating the QS response to alert the immune system to bacteria hiding in a low cell density. QS represents a recently discovered method of bacterial communication and population control, which may prove to be a unique mechanism to prevent, suppress, and/or treat infectious diseases.

Indexed as

AnimalsAnti-Bacterial AgentsCell CommunicationGene Expression Regulation, BacterialPseudomonas aeruginosaPseudomonas InfectionsQuorum SensingSignal TransductionStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial Agents

Identifiers

PMID18322716
OpenAlexW2128773944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.